Risk stratification and advancing precision therapy strategies for Oral Squamous Cell Carcinoma (OSCC) through the integration of Nanotechnology-enhanced Nutritional interventions with comprehensive Randomized controlled Trials: Exploring the Therapeutic potential of targeting Iron-Responsive Elements (IREs) and their binding proteins.

Oral Squamous Cell Carcinoma (OSCC) remains a significant global health challenge due to its aggressive nature and poor prognosis in advanced stages. Traditional therapeutic approaches often fall short in effectively addressing the heterogeneity and complexity of OSCC. To improve outcomes, there is a pressing need for strategies that offer precise risk stratification and tailored therapeutic interventions.

The trial seeks to advance precision therapy for OSCC by integrating cutting-edge nanotechnology-enhanced nutritional interventions within the framework of comprehensive randomised controlled trials (RCTs). Specifically, the trial will explore the therapeutic potential of targeting Iron-Responsive Elements (IREs) and their binding proteins, which play a critical role in cellular iron metabolism and have been implicated in cancer progression. By focusing on these molecular targets, the trial aims to develop more effective, personalized treatment strategies that could lead to better management and prognosis of OSCC.